$BIO News

Bio-Rad to Report Third-Quarter 2026 Financial Results on Wednesday, November 4, 2026

Cell Isolation / Cell Separation - Global Strategic Business Report: Secure Share of a US$42.8 Billion Market by 2030 as BD Biosciences, Beckman Coulter, Bio-Rad and Thermo Fisher Accelerate

Why Bio Rad Laboratories (BIO) Is Back In The Spotlight

Bio-Rad Laboratories Bets on Digital PCR, Margins and Smarter M&A Growth

Bio-Rad Laboratories, Inc. (BIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript

Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum

Bio Rad (BIO) Stock Could Be 23% Overvalued As Column Expansion Continues

Bio-Rad: Favorable Read-Across From Investor Event

Bio-Rad Laboratories, Inc. (BIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 21st Annual Healthcare Conference

Bio-Rad Laboratories (BIO) Price Target Increased by 10.39% to 346.80

Bio-Rad (BIO) Q2 2026 Earnings Call Transcript

Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock

Bio Rad Laboratories (BIO) Earnings And Guidance Put Fair Value Back In Focus

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $390

Citigroup Maintains Neutral on Bio-Rad Laboratories, Raises Price Target to $330

Bio-Rad Laboratories, Inc. Q2 2026 Earnings Call Summary

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Raises Price Target to $370

Wells Fargo Maintains Equal-Weight on Bio-Rad Laboratories, Raises Price Target to $330